Point72 (DIFC)’s Terns Pharmaceuticals TERN Stock Holding History

Point72 (DIFC)’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,948	Closed	-$33K	–	2083
2025 Q1	$33K	Buy	+11,948	New	+$48.8K	﹤0.01%	1282

Other funds holding TERN

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Point72 (DIFC)'s TERN Position: Q2 2025 in Review

Point72 (DIFC) sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 11,948 shares — an estimated $33K sold.

Point72 (DIFC) first reported a position in TERN in Q1 2025 and held it in 1 quarter. The position peaked at $33K in Q1 2025. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

Point72 (DIFC) reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Point72 (DIFC) sold 11,948 Terns Pharmaceuticals shares in Q2 2025, an estimated $33K.
Point72 (DIFC) first reported a position in Terns Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Point72 (DIFC)'s Terns Pharmaceuticals position peaked at $33K in Q1 2025.
129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.